Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma. Issue 7 (4th September 2014)
- Record Type:
- Journal Article
- Title:
- Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma. Issue 7 (4th September 2014)
- Main Title:
- Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma
- Authors:
- Li, Zongtai
Zou, Xiaofang
Xie, Liangxi
Chen, Hongcai
Chen, Yuping
Yeung, Sai‐Ching Jim
Zhang, Hao - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Gastroesophageal junction adenocarcinoma (GEJA) is an aggressive malignancy with an alarmingly rising incidence. TNM staging is widely used by oncologists to stratify prognosis as well as direct therapeutic strategies. However, inadequate lymphadenectomy is frequently encountered for GEJA and largely confounds prognosis resulting from TNM staging. Thus, a molecular biomarker, which can accurately forecast the risk of nodal metastasis in patients with inadequate lymphadenectomy, is required to guide precisely clinical decision. In this study, bioinformatics and pathological analysis identified that p21 protein‐activated kinase 1 (PAK1) is associated with lymph nodal metastasis of GEJA. The PAK1 H‐score was lower in the patients with negative lymph nodes than that in patients with positive (metastatic) lymph nodes (6.865 ± 3.376, 9.370 ± 2.530, respectively; <italic>p</italic> &lt; 0.001). The PAK1 H‐score in lymph nodes was positively correlated with that in primary tumors (PTs; <italic>p</italic> &lt; 0.001; <italic>r</italic> = 0.475). PAK1 H‐scores in PTs had the best performance based on its area under the receiver–operating characteristic (ROC) curve compared with PAK1 H‐scores in lymph nodes, histological grade, lymph nodal metastasis status, tumor size, depth of tumor, TNM stage and number of resected lymph nodes. Multivariate Cox proportional hazard and Fine and Gray models showed<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Gastroesophageal junction adenocarcinoma (GEJA) is an aggressive malignancy with an alarmingly rising incidence. TNM staging is widely used by oncologists to stratify prognosis as well as direct therapeutic strategies. However, inadequate lymphadenectomy is frequently encountered for GEJA and largely confounds prognosis resulting from TNM staging. Thus, a molecular biomarker, which can accurately forecast the risk of nodal metastasis in patients with inadequate lymphadenectomy, is required to guide precisely clinical decision. In this study, bioinformatics and pathological analysis identified that p21 protein‐activated kinase 1 (PAK1) is associated with lymph nodal metastasis of GEJA. The PAK1 H‐score was lower in the patients with negative lymph nodes than that in patients with positive (metastatic) lymph nodes (6.865 ± 3.376, 9.370 ± 2.530, respectively; <italic>p</italic> &lt; 0.001). The PAK1 H‐score in lymph nodes was positively correlated with that in primary tumors (PTs; <italic>p</italic> &lt; 0.001; <italic>r</italic> = 0.475). PAK1 H‐scores in PTs had the best performance based on its area under the receiver–operating characteristic (ROC) curve compared with PAK1 H‐scores in lymph nodes, histological grade, lymph nodal metastasis status, tumor size, depth of tumor, TNM stage and number of resected lymph nodes. Multivariate Cox proportional hazard and Fine and Gray models showed that histological grade 3, Charlson comorbidity index &gt; 7 and high PAK1 expression in PTs were associated with significantly increased risk of recurrence and cancer‐related death. In conclusion, high PAK1 expression in PTs is predictive of node metastasis and can be easily integrated in the clinical decision process for personalized therapeutics of GEJA.</p> </abstract> … (more)
- Is Part Of:
- International journal of cancer. Volume 136:Issue 7(2015:Apr. 01)
- Journal:
- International journal of cancer
- Issue:
- Volume 136:Issue 7(2015:Apr. 01)
- Issue Display:
- Volume 136, Issue 7 (2015)
- Year:
- 2015
- Volume:
- 136
- Issue:
- 7
- Issue Sort Value:
- 2015-0136-0007-0000
- Page Start:
- 1636
- Page End:
- 1645
- Publication Date:
- 2014-09-04
- Subjects:
- Cancer -- Periodicals
Cancer -- Prevention -- Periodicals
616.994 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0215 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/ijc.29167 ↗
- Languages:
- English
- ISSNs:
- 0020-7136
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.156000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3650.xml